Insmed (NASDAQ:INSM) Given Buy Rating at HC Wainwright

Insmed (NASDAQ:INSM)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $230.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 39.47% from the stock’s previous close.

A number of other brokerages have also issued reports on INSM. Wolfe Research set a $167.00 target price on Insmed and gave the company an “outperform” rating in a research report on Thursday, December 18th. Cantor Fitzgerald increased their target price on Insmed from $216.00 to $230.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. UBS Group decreased their target price on Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a research report on Tuesday, January 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a research report on Thursday, January 22nd. Finally, Citigroup reaffirmed an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $207.86.

Insmed Stock Performance

Shares of INSM stock opened at $164.91 on Monday. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. The company’s fifty day moving average price is $165.12 and its two-hundred day moving average price is $163.89. The firm has a market capitalization of $35.55 billion, a P/E ratio of -25.73 and a beta of 1.11. Insmed has a 12 month low of $60.40 and a 12 month high of $212.75.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The business had revenue of $263.84 million for the quarter, compared to analysts’ expectations of $263.97 million. During the same period in the previous year, the firm posted ($1.32) earnings per share. The firm’s revenue was up 152.6% compared to the same quarter last year. On average, research analysts anticipate that Insmed will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Roger Adsett sold 791 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $156.17, for a total value of $123,530.47. Following the sale, the chief operating officer owned 106,810 shares of the company’s stock, valued at $16,680,517.70. This trade represents a 0.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO William Lewis sold 13,396 shares of Insmed stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $147.79, for a total transaction of $1,979,794.84. Following the completion of the sale, the chief executive officer owned 301,185 shares in the company, valued at approximately $44,512,131.15. This represents a 4.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 168,253 shares of company stock valued at $28,606,942 over the last three months. Corporate insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Insmed

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INSM. Vanguard Group Inc. raised its stake in Insmed by 5.7% during the 4th quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock valued at $3,668,127,000 after acquiring an additional 1,140,524 shares in the last quarter. Darwin Global Management Ltd. increased its holdings in shares of Insmed by 2.3% during the fourth quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company’s stock valued at $3,644,274,000 after purchasing an additional 475,832 shares during the period. Capital International Investors raised its stake in shares of Insmed by 1.0% during the third quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock valued at $1,087,830,000 after purchasing an additional 74,994 shares in the last quarter. State Street Corp lifted its holdings in Insmed by 30.6% in the fourth quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock worth $905,312,000 after purchasing an additional 1,217,390 shares during the period. Finally, Artisan Partners Limited Partnership lifted its holdings in Insmed by 49.0% in the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after purchasing an additional 1,623,342 shares during the period.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.